Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab, Chidamide, and Azacitidine in Relapsed/Refractory PTCL
NCT04052659Phase 2Not yet recruiting
- Sponsor
- Peking University
- Start
- Apr 2021
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in peripheral T-cell lymphoma (PTCL), sponsored by Peking University. Planned start Apr 2021; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT04052659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04052659.